products was SPINRAZA. XXth may some Thank some that of and a its the in Bioverativ, until you, you It anniversary, recently have we on really as is celebrated that Mike. recall and this company past, has Biogen spun-off had built been it sclerosis. has hemophilia multiple
transform business? really to about do the think we need now how we So
do the that how we be about are the we more business I to therefore, know to a firsthand from is number becoming the to MS in obviously, grow much in competitive of products. environment. neurologists need talking a still considered top But our this really And think products future.
of major new many been this two as have products, amazing but it's really a products and not I've respective in have opportunity pretty and quite that you but opportunity you time, two that one we Now business launch rare to in this long know, areas, zuranolone. and transformative an products. LEQEMBI their And the any just obviously with therapeutic products are that's and not
We two existing And reinvigorate and also of have to a grow products. grow think those to need SPINRAZA. still I take to We can We growth try still the those brands. can we fresh approach VUMERITY.
out of has cost As will many you probably of peers. that its is me, a to most base higher than Biogen point
to about systematically. need more we much think that And
in of And some cost. a that may reduction require
realignment the new alternatives. at look And actually R&D a Some also need then growth the we is with of it to pipeline.
talk you Now franchise credit Priya of [technical about have very difficulty] number we much the that what potential. a slowly is to we products different Equally, don't we R&D, and of have progressing neurology going for diseases. to an think lot is get awful in
into III means you're projects are and some That studies our essentially in we where clinical proof-of-concept costly studies. automatically studies. long-term Phase And there addition, in have
think makes think balance inherently in that pipeline so And how forward. to them going I R&D the also about riskier. we we do And need
external as we should immunology, areas there growth always external thrust we opportunities that company franchises through And should that as company in always about growth. diseases, open any past. -- thinking of may major bolster to be I finally, expand a always into such be rare do the the other been But opportunities. those psychiatry, think This be hasn't think I to
So received as you has in United LEQEMBI know, States in the approval accelerated early January.
short on have And same and filed for in Eisai full initiated I the to did also they for of approval. within period only or traditional China. a as a on a in not Japan same have, file to very approval our partner, the within time, also receiving rolling traditional filed day, submission give day credit We but they Europe, weeks, approval have in, in accelerated because
to priority launch the we have have FDA, get the not. in occur constricted until in obviously, that's filing and be or going expected When And confirmation of point, approval. know short a from traditional is once that to we'll we to we review really whether U.S. at reimbursement, we get the a the term,
Under is with and the discussions agreement, the CMS. terms Eisai responsible of principally the leads all of
receive they could to as once you summer. approval that be said of traditional Eisai many reimbursement and hoping they As this get heard, as that probably has early have broader a are
as this is know, you here. a But not launching round pill that we're like
PET or lumbar Neurologists have a scan conditions. confirm going puncture to treating a have other to We're capacity need infusion to patients busy with diagnosis. already You restrictions. have been
enough done in population? to neurologists the about to lot will patient there's And an be the be expand a there we near do So awful term. have question so
CMS. the that is the terms of be -- In that will and main -- up of questions for the comes discussion one
look we the To CDR-sum me, is here. boxes at benefit not how the of of patient boxes, really sum
I are I to car? I patients, with a And enjoy myself? As most how drive still my Alzheimer's to myself? be life I of can burden talk not physicians them Can others? Can family? asking, dress a I I treating can Can really feed
And product where XX% when real a improvement me, versus daily we to saw you at the placebo. actually this activities look actually of of life, the that's And is. benefit
to Now as today this we is look it launch, and there is I drive think is there just other a that would really not is tomorrow. home I product message today a at like Alzheimer's, the
that be of and the everybody that's really lot overcoming of of diagnosis to field. around scans question provide is the going infrastructure or LEQEMBI up be be is to about. and able infrastructure opening challenges focused some the CSF to the going around a of has just the we talked education There's awful be And But whole testing. certainly, on this the to today, initial new of to sales to safety, physicians going PET a an expand
years and new hope physicians. in had where of to this study for potential can of is vista, up was failures and given it's of it XX People be impact a XX both the cognition. PRIME that effective. This has still study had the that hope ago, development lot about there whole really course, importance CLARITY really initiated Biogen's of going we've of the to in years And reduce that patients Actually, amyloid. was this. medicines to remember decline was a demonstrated showed that actually ago for I was that removal plaque the
I we're think mean is other things. potential talk there's And there Priya about but whole do be of to amyloid, to going are other to our this there's is things a as research going such tau. development, and doing. terms just modalities what and but that in own tau, wave Obviously, of even going will unleash be I solution
at are on the XX data that already XX staying benefit. this continued months months? -- also has actually indicate of the focused end there trial What the treatment. happens a we're really But at on looking of this And drug
over QX of basis. learned, just get end and And fact, been speed at days, Alzheimer's out so the Eisai on I've turns its symptoms treatment to be the I it things this indication a obviously in of year, to But maintenance up XX interesting but last the will that the maximum an plaque of one before filing trying burden is arise. for on before most other
benefit are or be presymptomatic patients and So ahead going fact, if is or things imagine biomarkers be to course, of called actually we But at blood-based that important. another go is that study like could biomarkers in interesting. earlier preclinical could a quite looking do the to that, other there a
have to subcutaneous treatment in progress. convenient as lot a We're this and there's a going treatment formulations more to make
over is to information just And patients modalities years, next think and treating a three the ways flood Alzheimer's to of so what see new of I up. come new five going as you're
see you here, the presymptomatic. at So launched that and XXXX was in AHEAD study looking
Alzheimer think until X- physicians a as the death. about which really of who timeframe, the Alzheimer's One was to has to of symptoms told from we used treat onset X-year sadly me,
up looking frame cognitive it's in we not. a today because And early-stage call improvement, builds know Alzheimer's this we they're that or at with fact, on what really Now time. plaque mild XX-year this over
dosing the talked It's modalities. actually for pretty and maintenance already about advanced We already MCI. you potential by different have time the
to an this exciting going area, go So is we be as along. quite
there And about reading who disorder. the society. this. depressive day, major you're XX suffer mental health million and in people concerns And every areas around are exciting other the major Now from
people fact, sad an [ph] from just about depression and are feeling In who article younger suffering STEP had number even of suicidal. and yesterday the
new clear And is need a for treatments. there so
a XXX every over written what of lot medical long these existing is an year MDD There's lot between side time other for these But new medicines health. million concern switching There around see takes medicine awful It work. effects. -- we and to therapies. a for are of prescriptions
cannot when GlaxoSmithKline lot pretty and the treatments awful existing was And an there's had unmet at so my need. I'm with I had Paxil can is So we personal we of do. view familiar what and
depression, had unmet Boston a a one and approach many we area in need demonstrates new eight as tragic need, mothers, another following, significant there the case, is us of for here. just Postpartum a that area treatment and in real of just new it
where necessarily change zuranolone not but there is societal I big is this think here. big a need opportunity And commercial a and a can make that major is,
granted, So we August. have priority we in now a PDUFA have and review had a date
you As because can't can the the of to a know, have we of immediately be launch. review will launch we it drug scheduling before DAA
we're towards year. the the more looking launch to of So end
of then because media every One six of this the zuranolone trials the positive. in seven see is now and I of interesting controversial things out the data about were
III to ago, developing to placebo many here, effect companies to we Paxil health. which get do is incredible Phase studies actually mental an There's six were we why Folks, when abandon so had worked. that years
when So this of I saw absolutely seven, terrific. six is I out "Well, said,
And is here." an so exciting I opportunity think quite there
We're depression early right type to of we that us not and the this. out will who's lot obviously, doing for we're of who will we're But study patient go of And going mid-market symptoms there. Today, SHORELINE the a label inform research. after the there's and of finishing lot unresolved patient, about a interested. are inform every
who we MDD going but adherence-challenged. an patients and anxiety, of we're clearly that with that an elevated be patients anxiety MDD focusing indication, on area those to is won't have are
we're lot have had drugs. of a say, I'll can there at enormous been obviously, have a potential when it, Going coverage treated as with patients. success But as well fresh SPINRAZA. Biogen just And still look at product. existing look patients going improve you the patients of to adult that this are how to back pediatric we
is which product, necessarily intrathecal an most it's the convenient. Obviously, not
not with to through have for go lumbar device who a punctures. seen the numerous patients we've would have wanting may a collaboration You just new that are make convened Alcyone more done this to
We are of we shift product of the franchise. profitability new these looking our at Can at costs, supporting looking that's MS our costs to launches. some
maybe the on businesses, the biosimilars This part whether economies can more a business, is do others with we business. important an are for health create that looking business the new business. whether system have we we way We at but care could this of for or that
about a our near-term systematic at We're is going opportunities and risk prioritizing profile looking the and the really of basis. Priya cost R&D base productivity talk to on the pipeline.
Head earlier, that. to I'd mentioned take opportunity I Development, As of we have appointed Priya her on as like congratulate the to
for We're Research. also looking new Head of a
While we opportunities. external continue have evaluate a lot growth going to on,
think And talk that, we I Priya, R&D? why about with so don't
